Moleculin Biotech Inc (MBRX) Actualités

Form 8-K - Current report

Form 8-K - Current report

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML PR Newswire HOUSTON, Nov...

Form 8-K - Current report

Form 8-K - Current report

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML...

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in...

Form 8-K - Current report

Form 8-K - Current report

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire HOUSTON, Nov...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and...